4.6 Article

Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01

Journal

ECLINICALMEDICINE
Volume 40, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.eclinm.2021.101099

Keywords

SARS-CoV-2; COVID-19; Genetics; Human Leukocyte Antigen intubation

Funding

  1. Roche Sequencing Solutions, Inc.
  2. Swiss National Science Foundation
  3. Berlin Institutes of Health (B.I.H.)
  4. National Institutes of Health: NIH [K01-HL130704]
  5. Silesian University of Technology grant for Support and Development of Research Potential
  6. NIAID-NIH CEIRS contract [HHSN272201400008C]
  7. NIH [R35 HL140026]
  8. German Research Foundation [SFB-TR84, SFB 1449]
  9. German Ministry of Education and Research (BMBF) [01ZX1304B, 01ZX1604B, 01ZX1906A, 01KI20160A, 16GW0141, 16GW0247, 01KX2021]
  10. Berlin Institute of Health (CM-COVID)
  11. German Research Foundation (DFG)
  12. Open Access Publication Fund of Charite - Universitatsmedizin Berlin

Ask authors/readers for more resources

The HLA-C*04:01 genotype is associated with severe clinical course in COVID-19 patients, doubling the risk of intubation when infected with SARS-CoV-2. This finding is corroborated by meta-analyzed data and independent results, and is biologically plausible.
Background: Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there has been increasing urgency to identify pathophysiological characteristics leading to severe clinical course in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Human leukocyte antigen alleles (HLA) have been suggested as potential genetic host factors that affect individual immune response to SARS-CoV-2. We sought to evaluate this hypothesis by conducting a multicenter study using HLA sequencing. Methods: We analyzed the association between COVID-19 severity and HLAs in 435 individuals from Germany (n = 135), Spain (n = 133), Switzerland (n = 20) and the United States (n = 147), who had been enrolled from March 2020 to August 2020. This study included patients older than 18 years, diagnosed with COVID19 and representing the full spectrum of the disease. Finally, we tested our results by meta-analysing data from prior genome-wide association studies (GWAS). Findings: We describe a potential association of HLA-C*04:01 with severe clinical course of COVID-19. Carriers of HLA-C*04:01 had twice the risk of intubation when infected with SARS-CoV-2 (risk ratio 1.5 [95% CI 1.1-2.1], odds ratio 3.5 [95% CI 1.9-6.6], adjusted p-value = 0.0074). These findings are based on data from four countries and corroborated by independent results from GWAS. Our findings are biologically plausible, as HLA-C*04:01 has fewer predicted bindings sites for relevant SARS-CoV-2 peptides compared to other HLA alleles. Interpretation: HLA-C*04:01 carrier state is associated with severe clinical course in SARS-CoV-2. Our findings suggest that HLA class I alleles have a relevant role in immune defense against SARS-CoV-2. Funding: Funded by Roche Sequencing Solutions, Inc. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available